Skip to main content
. 2018 Aug 21;2018(8):CD012317. doi: 10.1002/14651858.CD012317.pub2

NCT03165396.

Trial name or title Appropriate compatibility of propofol and sevoflurane for orthopaedic surgery of patients with MCI
Methods RCT, parallel design
Participants Target number of randomized participants: 100
Inclusion criteria
  1. Scheduled for elective orthopaedic surgery, ASA II, 50 to 75 years


Exclusion criteria
  1. Neurological diseases that may affect cognitive function (e.g. subdural haematoma)

  2. Hypothyroidism

  3. Alcoholic dementia


Type of surgery: orthopaedic surgery
Country: China
Setting: hospital
Interventions TIVA group
Details: propofol TCI 2.0 to 2.5 μg/mL
Inhalational maintenance group
Details: 1.3 MAC sevoflurane
Outcomes
  1. Evidence of clinically cognitive function decline (using ApoJ, at 7 days; soluble CD14, at 7 days)

  2. Cognitive function (using MMSE, at 24 hours and 7 days postoperatively; and MoCA, at 24 hours and 7 days postoperatively)

Starting date 10 May 2016
Contact information Haiyun Wang (why@126.com) or Yimeng Chen (chenyimeng5525@163.com)
Notes Compares two additional groups using propofol at different doses combined with sevoflurane